Two-phase II trials testing IL-17A-inhibitor agents in patients with Crohn’s disease were terminated due to increased occurrence of adverse events as well as an increased disease activity in the treatment group compared to the placebo group [7, 8]. Here, IL17A is linked to Crohn disease.